Medpace Holdings, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Medpace Holdings, Inc. (MEDP) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $11.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-07-23
- Medpace Holdings, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $6.05M, a 7.65% increase year-over-year.
- Medpace Holdings, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $5.85M, a 3.55% decline year-over-year.
- Medpace Holdings, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $5.68M, a 2.30% decline year-over-year.
- Medpace Holdings, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $5.64M, a 3.46% decline year-over-year.
- Medpace Holdings, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $23.01M, a 0.48% decline from fiscal 2024.
- Medpace Holdings, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $23.12M, a 17.70% increase from fiscal 2023.
- Medpace Holdings, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $19.65M, a 9.05% increase from fiscal 2022.
- Medpace Holdings, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $18.02M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $11.90M 10-Q · filed 2026-07-23 | $17.59M derived: sum of 3 quarters · filed 2026-07-23 | $23.23M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $5.85M 10-Q · filed 2026-04-23 | $11.53M derived: sum of 2 quarters · filed 2026-04-23 | $17.18M derived: sum of 3 quarters · filed 2026-04-23 | $22.80M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $5.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $11.33M derived: sum of 2 quarters · filed 2026-02-10 | $16.95M derived: sum of 3 quarters · filed 2026-07-23 | $23.01M 10-K · filed 2026-02-10 |
| 2025-09-30 | $5.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $11.27M derived: sum of 2 quarters · filed 2026-07-23 | $17.33M 10-Q · filed 2025-10-23 | $23.15M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $5.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $11.69M 10-Q · filed 2026-07-23 | $17.51M derived: sum of 3 quarters · filed 2026-07-23 | $23.35M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $6.06M 10-Q · filed 2026-04-23 | $11.88M derived: sum of 2 quarters · filed 2026-04-23 | $17.73M derived: sum of 3 quarters · filed 2026-04-23 | $23.49M derived: sum of 4 quarters · filed 2026-04-23 |
| 2024-12-31 | $5.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $11.66M derived: sum of 2 quarters · filed 2026-02-10 | $17.43M derived: sum of 3 quarters · filed 2026-02-10 | $23.12M 10-K · filed 2026-02-10 |
| 2024-09-30 | $5.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $11.61M derived: sum of 2 quarters · filed 2025-10-23 | $17.30M 10-Q · filed 2025-10-23 | $22.37M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $5.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-22 | $11.46M 10-Q · filed 2025-07-22 | $16.53M derived: sum of 3 quarters · filed 2026-02-10 | |
| 2024-03-31 | $5.70M 10-Q · filed 2025-04-22 | $10.76M derived: sum of 2 quarters · filed 2026-02-10 | ||
| 2023-12-31 | $5.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $19.65M 10-K · filed 2026-02-10 | ||
| 2023-09-30 | $14.58M 10-Q · filed 2024-10-22 | |||
| 2022-12-31 | $18.02M 10-K · filed 2025-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |